Drug Profile

SNP 630

Alternative Names: SNP-630

Latest Information Update: 05 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sinew Pharma
Class Drug conjugates; Hepatoprotectants; Immunoconjugates
Mechanism of Action Cytochrome P-450 enzyme system inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Non-alcoholic steatohepatitis

Most Recent Events

05 Feb 2025 SNP 630 is still in phase I trials for Non-alcoholic steatohepatitis (In volunteers) in Taiwan (PO)
05 Feb 2025 Adverse events data from the preclinical studies in Non-alcoholic steatohepatitis released by Sinew Pharma (Sinew Pharma pipeline, February 2025)
28 Aug 2024 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis(In volunteers) in Taiwan (PO, Liquid)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com